<SEC-DOCUMENT>0001493152-26-012663.txt : 20260325
<SEC-HEADER>0001493152-26-012663.hdr.sgml : 20260325
<ACCEPTANCE-DATETIME>20260325160524
ACCESSION NUMBER:		0001493152-26-012663
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260325
FILED AS OF DATE:		20260325
DATE AS OF CHANGE:		20260325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nasus Pharma Ltd
		CENTRAL INDEX KEY:			0002029039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				516022712
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42796
		FILM NUMBER:		26792429

	BUSINESS ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
		BUSINESS PHONE:		972 54-255-3956

	MAIL ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the month of March 2026 (Report No. 4)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: 001-42796</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Nasus
Pharma Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>P.O.
Box 284</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel
Aviv, Israel 6100201</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Press
Release</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 25, 2026, Nasus Pharma Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;Nasus Pharma Advances NS002 Towards
Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update&rdquo;, a copy of which is furnished as
Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
INDEX</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release issued on March 25, 2026 by Nasus Pharma Ltd. titled &ldquo;Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update&rdquo;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SIGNATURE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
    PHARMA LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 25, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Teleman</FONT></I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Teleman</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasus
Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Recent
Phase 2 topline results demonstrate NS002&rsquo;s potential for best-in-class epinephrine delivery, with statistically significant improvements
in early absorption compared to EpiPen<SUP>&reg;</SUP>; pivotal study planned for Q4 2026</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Company
advancing pipeline assets NS003 (Ondansetron for chemotherapy-induced nausea and vomiting) and NS004 (metabolic) toward first-in-human
studies expected to start in the second half of 2026, significantly expanding the Company&rsquo;s intranasal product portfolio into additional
high value therapeutic areas</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Company
well funded through planned NS002 pivotal study and potential NDA submission</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TEL
AVIV, Israel, March 25, 2026 &mdash; Nasus Pharma Ltd. (NYSE: NSRX) (&ldquo;Nasus Pharma&rdquo; or the &ldquo;Company&rdquo;), a clinical-stage
pharmaceutical company focused on the development of innovative intranasal products, today announced the filing of its annual report
on Form 20-F for the year ended December 31, 2025, and provided a business update highlighting recent Phase 2 results for NS002 and upcoming
clinical milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;With
positive Phase 2 data for NS002 and a strong cash position, we believe Nasus is well positioned to deliver on multiple clinical inflection
points in 2026,&rdquo; said Dan Teleman, Chief Executive Officer of Nasus Pharma. &ldquo;Following the compelling topline Phase 2 results
of NS002, we are advancing our intranasal epinephrine powder formulation towards a pivotal study planned to initiate in the fourth quarter
of this year. The Company is well-funded to complete NS002&rsquo;s pivotal study and see through a potential NDA filing. In addition,
we plan to progress our earlier pipeline assets, Ondansetron for chemotherapy induced nausea and vomiting, and NS004 targeting metabolic
disorders, into first-in-human studies in the second half of the year and are also advancing NS005 targeting cardiovascular diseases.
We believe our pipeline of innovative intranasal products, leveraging our proprietary powder platform technology, can deliver significant
clinical benefits to patients and could unlock substantial value to our shareholders. We are committed to executing on this vision.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Business
Update</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NS002
&ndash; Intranasal powder Epinephrine for Anaphylaxis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="width: 0.25in">&#9679;</TD>
  <TD STYLE="text-align: justify"><B>Completed Phase 2 single and repeat dose clinical study</B>, with topline results demonstrating
  statistically significant improvements in time to therapeutic threshold (T100) and a higher proportion of participants reaching therapeutic
  epinephrine levels within the first minutes following administration, compared to EpiPen<SUP>&reg;</SUP>. The data also demonstrated
  NS002&rsquo;s consistent absorption across real-world conditions, including under a nasal allergic challenge designed to simulate anaphylaxis
  scenarios.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&#9679;</TD>
  <TD STYLE="text-align: justify"><B>Advancing toward pivotal development</B>, with a pivotal clinical study expected to initiate in the fourth quarter of 2026 and
  a planned readout in the first quarter of 2027, subject to regulatory alignment. The Company believes the positive Phase 2 results
  support continued development toward a potential NDA submission.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Early
Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
is advancing its earlier-stage pipeline programs, which leverage the Company&rsquo;s proprietary intranasal powder platform:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NS003</B>
                                            &ndash; Ondansetron for chemotherapy-induced nausea and vomiting</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NS004</B>
                                            &ndash; targeting metabolic disorders</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NS005
                                            </B>&ndash; targeting cardiovascular diseases</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
programs are currently in preclinical development, with first-in-human Phase 1 studies expected to initiate in the second half of 2026
for NS003 and NS004, supporting the continued expansion of the Company&rsquo;s intranasal product portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Financial
Results</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash,
Cash Equivalents and Marketable Securities</B>: As of December 31, 2025, Nasus had cash, cash equivalents and marketable securities
of $4.3 million, compared with cash and cash equivalents of $0.3 million as of December 31, 2024. The increase in cash, cash
equivalents and short term deposits was primarily a result of our IPO. Following our $15 private placement, which closed in February
2026, Nasus expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the
second quarter of 2027.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development Expenses</B>: Research and development expenses were $2.4 million for the year ended December 31, 2025, compared with
$0.3 million for the year ended December 31, 2024. The increase was primarily attributable to expenses paid in connection with the development
of NS002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative Expenses</B>: General and administrative expenses were $2.7 million for the year ended December 31, 2025, compared
with $0.7 million for the year ended December 31, 2024. The increase was mainly due to the company&rsquo;s transition to a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
Loss</B>: For the year ended December 31, 2025, net loss was $5.9 million compared with a net loss of $1.5 million for the year ended
December 31, 2024. The total number of shares outstanding as of December 31, 2025 was 9,015,383.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the &ldquo;Annual Report&rdquo;) with the U.S.
Securities and Exchange Commission (&ldquo;SEC&rdquo;), which can be accessed on its website at https://www.nasuspharma.com. Shareholders
may request, free of charge, a hard copy of the Annual Report, which includes the Company&rsquo;s complete audited consolidated financial
statements for the year ended December 31, 2025, by contacting ir@nasuspharma.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nasus Pharma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical
conditions in the community. NS002, Nasus Pharma&rsquo;s intranasal powder Epinephrine product candidate is being developed as a needle-free
alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations
in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma&rsquo;s proprietary powder-based
intranasal (&ldquo;PBI&rdquo;) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity&rsquo;s rich
vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially
faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit <U>www.nasuspharma.com</U>
or follow on <U>Twitter (X)</U> or <U>LinkedIn</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward
Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This press release contains &ldquo;forward-looking statements&rdquo; within the meaning of the Private Securities Litigation Reform
Act of 1995 and other U.S. federal securities laws. Words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo;
&ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo;
&ldquo;will&rdquo;, &ldquo;would,&rdquo; or the negative of these words, similar expressions or variations of such words are intended
to identify forward-looking statements. For example, Nasus Pharma is using forward looking statements in this press release when it discusses:
the timing and results of planned clinical studies, including the NS002 pivotal study, potential regulatory submissions, including a
potential NDA, the development and timing of pipeline programs, including NS003, NS004 and NS005, expected clinical and development milestones,
expansion of the Company&rsquo;s product portfolio, and the Company&rsquo;s financial position and expected cash runway. Historical results
of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest
identical or even similar conclusions. Forward-looking statements are based on the Company&rsquo;s current expectations and are subject
to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions
as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section
titled &ldquo;Risk Factors&rdquo; in the Company&rsquo;s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission
on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no
duty to update such information except as required under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus Pharma Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>info@nasuspharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mike Moyer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeSci Advisors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+1-617-308-4306</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>mmoyer@lifesciadvisors.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ '@# 2(  A$! Q$!_\0
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M\*2GT/\ :&^)G@4_\$\?%GQ8'@CX)_%W_A6/B;0_B!K_ ,56\._\)KK>MO\
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-LSL$0NS,"2444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
